Moxifloxacin HcL Dexamethasone

VIBMOXI D EYE DROP

COMPOSITION
Moxifloxacin HcL0.5%
Dexamethasone0.1%
SPECIFICATION
FORMEYE DROP
PACKING 5ML
PACKING TYPE1’s
MRP90

DESCRIPTION

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
An anti-inflammatory 9-fluoro-glucocorticoid. [PubChem]

SIDE EFFECTS

Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.

Oral, rat LD50: >3 gm/kg. Signs of overdose include retinal toxicity, glaucoma, subcapsular cataract, gastrointestinal bleeding, pancreatitis, aseptic bone necrosis, osteoporosis, myopathies, obesity, edemas, hypertension, proteinuria, diabetes, sleep disturbances, psychiatric syndromes, delayed wound healing, atrophy and fragility of the skin, ecchymosis, and pseudotumor cerebri.

INDICATION

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Injection: for the treatment of endocrine disorders, rheumatic D=disorders, collagen diseases, dermatologic diseases, allergic statesc, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, cerebral edema.

Ophthalmic ointment and solution: for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe.

Ophthalmic solution only: for the treatment of steroid responsive inflammatory conditions of the external auditory meatus

Topic cream: for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Oral aerosol: for the treatment of bronchial asthma and related corticosteroid responsive bronchospastic states intractable to adequate trial of conventional therapy

Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps”